---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-009136"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:37:42.942146+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%

## Summary
- Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.
- Diagnostics segment revenue $0.8M (+86%), driven by TRUFORMA platform adoption.
- Net loss $7.4M vs $23.9M (including $16M impairment) in Q2 2024; Adj. EBITDA loss $5.5M.
- Operating expenses down $0.7M excluding impairment; liquidity $59.1M.
- Record 18th consecutive quarter of YoY revenue growth; consumable sales up 21%.

## SEC filing metadata
- accession: 0001654954-25-009136
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/0001654954-25-009136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-009136
- JSON: https://secwatch.observer/filing/0001654954-25-009136.json
- Plain text: https://secwatch.observer/filing/0001654954-25-009136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.